TCTS

Tupan Launches the New Binance Smart Chain TCT

Retrieved on: 
Mercredi, mars 6, 2024

NEW YORK, NY, March 06, 2024 (GLOBE NEWSWIRE) -- Recently, Tupan has announced the launch of the new Binance Smart Chain TCT.

Key Points: 
  • NEW YORK, NY, March 06, 2024 (GLOBE NEWSWIRE) -- Recently, Tupan has announced the launch of the new Binance Smart Chain TCT.
  • Bitcoin recently surpassed the $46,000 mark on January 8th, due to recent compliance with the SEC and becoming an ETF and consequently a semi-security.
  • Tupan has started a never-before-seen program to enable its community to farm an Equity token called Tupan Augreen, which represents the shares of the ForestAu Green Investment Fund.
  • To acquire your TCTs before the exchange launch and discover this unique opportunity, join the exclusive list at www.tupan.io/launch

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Retrieved on: 
Lundi, août 28, 2023

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

Key Points: 
  • Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.
  • NorthStar is producing high-activity, high specific-activity and high-purity Cu-67 for use in Clarity’s clinical programs as part of an agreement to exclusively supply Cu-67 to Clarity.
  • NorthStar is the first commercial-scale supplier of this important Cu-67 therapeutic radioisotope, and Clarity leads the world in copper based theranostics.
  • NorthStar continues to drive commercial-scale innovation solutions for our industry, to meet the needs of patients and advance clinical research.

Leonardo DRS Earns Raytheon Technologies Premier Award

Retrieved on: 
Lundi, juillet 10, 2023

Leonardo DRS, Inc. (NASDAQ: DRS) announced today that its Airborne and Intelligence Systems business unit was awarded a Raytheon Technologies Premier Award for performance in 2022 and overall excellence in collaboration and customer service.

Key Points: 
  • Leonardo DRS, Inc. (NASDAQ: DRS) announced today that its Airborne and Intelligence Systems business unit was awarded a Raytheon Technologies Premier Award for performance in 2022 and overall excellence in collaboration and customer service.
  • The recognition is based on the partnership between Leonardo DRS and Raytheon’s Collins Aerospace division for the Tactical Combat Training System Increment II (TCTS II) program.
  • The Premier Award is an annual recognition platform under the Raytheon Technologies Performance+ Program to recognize suppliers with superior performance and that have provided exceptional value to Raytheon Technologies in one of the four key categories: cost competitiveness, technology and innovation, business management / customer service, and collaboration.
  • “We are extremely proud of our TCTS II team and their successful partnership with Collins Aerospace,” said Larry Ezell, senior vice president and general manager of the Leonardo DRS Airborne and Intelligence Systems business unit.

Clarity establishes a US Center of Excellence for Targeted Copper Theranostics

Retrieved on: 
Mercredi, juin 28, 2023

SYDNEY, June 28, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the establishment of a Center of Excellence at the Idaho Accelerator Center (IAC), a research facility operated by Idaho State University (ISU), for Targeted Copper Theranostics (TCTs).

Key Points: 
  • SYDNEY, June 28, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the establishment of a Center of Excellence at the Idaho Accelerator Center (IAC), a research facility operated by Idaho State University (ISU), for Targeted Copper Theranostics (TCTs).
  • The IAC is a unique research facility operated by ISU located in southeast Idaho, US.
  • Clarity is establishing the Center of Excellence at the IAC to advance research and development (R&D) of TCTs close to a source of copper-67 (Cu-67 or 67Cu) production.
  • I look forward to continuing to play my part in this new sector of cancer therapies at such an important time."

NorthStar Medical Radioisotopes Now Routinely Manufacturing High Activity Copper-67 on its Electron Accelerators for Clarity Pharmaceuticals' Therapy Clinical Programs

Retrieved on: 
Lundi, juin 26, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230626574624/en/
    NorthStar has successfully produced high activity, high specific activity and high purity Cu-67 and has supplied the isotope for use in Clarity’s clinical programs as part of an agreement for exclusive supply of the radioisotope to Clarity.
  • NorthStar is the first operational commercial-scale supplier of this important therapeutic radioisotope.
  • Our efforts use the proven expertise and innovative approach demonstrated in the successful development and commercialization of other non-uranium produced radioisotopes in the US.
  • We look forward to supporting Clarity’s plans for further clinical development and commercialization of Cu-67-based therapeutic radiopharmaceuticals to improve the lives of patients with serious disease.”

Raytheon Technologies to deliver Full Rate Production for TCTS Increment II Air Combat Training System for U.S. Navy

Retrieved on: 
Jeudi, mai 25, 2023

CEDAR RAPIDS, Iowa, May 25, 2023 /PRNewswire/ -- Collins Aerospace, a Raytheon Technologies business (NYSE: RTX) announced today it will deliver on the full rate production contract awarded by the U.S. Navy for Tactical Combat Training System – Increment II (TCTS II), Air Combat Training System (ACMI) for the U.S. Navy.

Key Points: 
  • CEDAR RAPIDS, Iowa, May 25, 2023 /PRNewswire/ -- Collins Aerospace, a Raytheon Technologies business (NYSE: RTX) announced today it will deliver on the full rate production contract awarded by the U.S. Navy for Tactical Combat Training System – Increment II (TCTS II), Air Combat Training System (ACMI) for the U.S. Navy.
  • The contract includes both airborne and ground subsystems and will support fielding requirements at various U.S. Navy training ranges.
  • TCTS II will be the foundation for next-generation training scenarios that will use a combination of live, virtual and constructive entities.
  • Developed and built by Collins Aerospace and teammate Leonardo DRS, TCTS II is a scalable and flexible open architecture system that enables highly secure air combat training among 4th and 5th Generation U.S. aircraft, and international aircraft.

Integrated Logistics Support Services Contract for PMA-205 Naval Aviation Training Systems Award to Synectic Solutions, Inc.

Retrieved on: 
Mercredi, mai 10, 2023

SSI, which is a certified Service-Disabled Veteran Owned company (SDVOSB) with 25 years of experience supporting Navy weapons and combat systems, has been awarded the Integrated Logistics Support Services Contract supporting multiple functional leads within PMA-205 Naval Aviation Training Systems located in Patuxent River, MD.

Key Points: 
  • SSI, which is a certified Service-Disabled Veteran Owned company (SDVOSB) with 25 years of experience supporting Navy weapons and combat systems, has been awarded the Integrated Logistics Support Services Contract supporting multiple functional leads within PMA-205 Naval Aviation Training Systems located in Patuxent River, MD.
  • Through this award, SSI will provide PMA-205 Integrated Logistics Product Support services for the acquisition, sustainment, and lifecycle support of specified Tactical Training Range (TTR) programs, including Ocean Systems (to include Portable Underwater Training Range (PUTR II); Undersea Warfare Training Range (USWTR); Air Combat Maneuvering Instrumentation (ACMI) and Electronic Warfare), Tactical Combat Training System Increments I (TCTS I), and Tactical Combat Training System (TCTS II) System of Systems (SoS).
  • This award will allow SSI to continue to provide the resources necessary to plan, manage, and integrate the design, development, acquisition, delivery, and sustainment of naval aviation training systems, training ranges, and products for PMA-205.
  • These products include the training systems, support equipment, and the product support packages to meet the Warfighters' required availability at optimal lifecycle costs.

Green Hills Software Thanks Collins Aerospace for Including the TCTS II Program in Their Recent FACE White Paper

Retrieved on: 
Mercredi, avril 26, 2023

SANTA BARBARA, Calif., April 26, 2023 /PRNewswire/ -- Green Hills Software, today, is thanking Collins Aerospace for highlighting the Tactical Combat Training System (TCTS) Increment II program in the technical white paper "Face 3.1 Enhancements: What Could Possibly Go Wrong?". Coauthored with LDRA and Lynx Software Technologies, the white paper highlights how conformance to the FACE™ Technical Standard is vital to the TCTS II program. Because Lynx is a coauthor of the white paper, some readers might come to the erroneous conclusion that a Lynx product is being used for the TCTS II program when it really is the INTEGRITY®-178 tuMP™ real-time operating system (RTOS) from Green Hills Software. The TCTS II program exclusively uses the FACE certified INTEGRITY-178 tuMP RTOS.

Key Points: 
  • SANTA BARBARA, Calif., April 26, 2023 /PRNewswire/ -- Green Hills Software, today, is thanking Collins Aerospace for highlighting the Tactical Combat Training System (TCTS) Increment II program in the technical white paper "Face 3.1 Enhancements: What Could Possibly Go Wrong?"
  • Coauthored with LDRA and Lynx Software Technologies, the white paper highlights how conformance to the FACE™ Technical Standard is vital to the TCTS II program.
  • Because Lynx is a coauthor of the white paper, some readers might come to the erroneous conclusion that a Lynx product is being used for the TCTS II program when it really is the INTEGRITY ® -178 tuMP ™ real-time operating system (RTOS) from Green Hills Software.
  • The TCTS II program exclusively uses the FACE certified INTEGRITY-178 tuMP RTOS.

Cubic Delivers 1000th P5 Internal Subsystem for the F-35

Retrieved on: 
Mardi, août 23, 2022

Cubic Corporation announced that the Cubic Mission and Performance (CMPS) division successfully delivered the 1000th P5 Combat Training System (P5CTS) for the F-35 aircraft, a significant milestone in military innovation.

Key Points: 
  • Cubic Corporation announced that the Cubic Mission and Performance (CMPS) division successfully delivered the 1000th P5 Combat Training System (P5CTS) for the F-35 aircraft, a significant milestone in military innovation.
  • The F-35 P5 is an Internal Subsystem (IS) configuration that relays encrypted Time, Space and Position Information (TSPI) between participating aircraft and range ground stations during training sorties.
  • This system is fully interoperable with the P5 Combat Training System (CTS) / Tactical Combat Training System Increment I (TCTS I) ACMI system.
  • Cubic is pleased to deliver our 1000th P5CTS for the F-35 Enterprise, said Jonas Furukrona, vice president and general manager of LVC Training, CMPS.

Dr Neal Shore joins Clarity's Clinical Advisory Board

Retrieved on: 
Jeudi, mai 26, 2022

SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Neal Shore has joined Clarity's Clinical Advisory Board (CAB).

Key Points: 
  • SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Neal Shore has joined Clarity's Clinical Advisory Board (CAB).
  • Dr Shore MD, FACS is the Chief Medical Officer of Urology/Surgical Oncology at GenesisCare, US and the Medical Director of Carolina Urologic Research Centre.
  • Clarity's Executive Chairman, Dr Alan Taylor, commented,"We are very pleased to welcome Dr Shore to our CAB.
  • Dr Shore has more than 250 peer reviewed publications and numerous book chapters.